Press Releases

Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.

Upperton Pharma Solutions Awarded VaxHub Sustainable Grant to Advance Oral Vaccine Delivery in Partnership with the University of Oxford’s Pandemic Sciences Institute.

Tuesday, August 19, 2025

Upperton Pharma Solutions a leading UKbased contract development and manufacturing organisation CDMO has been awarded a grant as part of the first VaxHub Sustainable Platform Funding Call

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Tuesday, August 19, 2025

Tonix Pharmaceuticals Holding Corp Nasdaq TNXP a fullyintegrated biotechnology company today announced that the US Food and Drug Administration FDA approved Tonmya cyclobenzaprine HCl sublingual tablets for the treatment of fibromyalgia in adults Ton...

Clarivate Launches AI-powered Regulatory Assistant Within Cortellis Suite to Boost Productivity and Ease Regulatory Burden

Saturday, August 16, 2025

Clarivate Plca leading global provider of transformative intelligence today announced the beta launch of its AIpowered Regulatory Assistant within Cortellis Regulatory Intelligence This new capability is designed to help regulatory professionals navi...

Pilatus Biosciences Announces Clinical Trial Collaboration with Roche to Evaluate PLT012 in First-in-Human Study in Hepatocellular Carcinoma

Thursday, August 14, 2025

Pilatus Biosciences Inc a biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers today announced a clinical trial collaboration with Roche

Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease

Thursday, August 14, 2025

The European Medicines Agency has granted orphan designation to rilzabrutinib a reversible covalent Brutons tyrosine kinase BTK inhibitor for IgGrelated disease IgGRD EMA grants orphan designation

Santhera signs agreement with GEN for the distribution of AGAMREE® (vamorolone) in Turkey

Wednesday, August 13, 2025

Santhera Pharmaceuticalsannounces the signing of an exclusive agreement with Gen la ve Salk rnleri San ve Tic A GEN for the distribution and commercialization of AGAMREE vamorolone in Turkey for the treatment of Duchenne muscular dystrophy DMD in pat...

AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.

Wednesday, August 13, 2025

AbbVietoday announced a million investment in its North Chicago Illinois manufacturing plant to expand domestic active pharmaceutical ingredient API production in the US This expansion is part of AbbVies previously

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Tuesday, August 12, 2025

Novartis today announced positive topline results from its Phase III trials evaluating ianalumab VAY in adults with active Sjgrens disease Both trials met the primary endpoint of demonstrating statistically

PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

Tuesday, August 12, 2025

Pfizer Incand Astellas Pharma Inc today announced positive topline results from the Phase EV clinical trial also known as KEYNOTE The EV study is evaluating PADCEV enfortumab vedotin

US NCI Sponsors Senhwa Biosciences' Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma

Friday, August 08, 2025

Senhwa Biosciences Inc a new drug development company focusing on firstinclass therapeutics for oncology rare diseases and infectious diseases today announced that US National Cancer Institute NCI sponsors